tiprankstipranks
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV

Enlivex Therapeutics Stock Analysis & Ratings

ENLV Stock Chart & Stats

Day’s Range$3.96 - $4.28
52-Week Range$3.65 - $13.95
Previous Close$4.07
Volume90.40K
Average Volume (3M)73.40K
Market Cap$57.62M
P/E Ratio-5.3
Beta1.09
Next EarningsMay 27, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score1
EPS (TTM)-0.81


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ENLV FAQ

What was Enlivex Therapeutics’s price range in the past 12 months?
Enlivex Therapeutics lowest stock price was $3.65 and its highest was $13.95 in the past 12 months.
    What is Enlivex Therapeutics’s market cap?
    Enlivex Therapeutics’s market cap is $57.62M.
      What is Enlivex Therapeutics’s price target?
      The average price target for Enlivex Therapeutics is $15.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $15.00 ,the lowest forecast is $15.00. The average price target represents 250.47% Increase from the current price of $4.28.
        What do analysts say about Enlivex Therapeutics?
        Enlivex Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Enlivex Therapeutics’s upcoming earnings report date?
          Enlivex Therapeutics’s upcoming earnings report date is May 27, 2022 which is in 11 days.
            How were Enlivex Therapeutics’s earnings last quarter?
            Currently, no data Available
            Is Enlivex Therapeutics overvalued?
            According to Wall Street analysts Enlivex Therapeutics’s price is currently Undervalued.
              Does Enlivex Therapeutics pay dividends?
              Enlivex Therapeutics does not currently pay dividends.
              What is Enlivex Therapeutics’s EPS estimate?
              Enlivex Therapeutics’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Enlivex Therapeutics have?
              Enlivex Therapeutics has 13,460,000 shares outstanding.
                What happened to Enlivex Therapeutics’s price movement after its last earnings report?
                Currently, no data Available
                Which hedge fund is a major shareholder of Enlivex Therapeutics?
                Among the largest hedge funds holding Enlivex Therapeutics’s share is ARK Investment Management LLC. It holds Enlivex Therapeutics’s shares valued at 2M.

                  ---

                  Enlivex Therapeutics Stock Analysis

                  Smart Score
                  1
                  Underperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  Price Target
                  $15.00
                  ▲(250.47% Upside)
                  Moderate Buy
                  The Enlivex Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Enlivex Therapeutics Ltd

                  Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Benitec Biopharma
                  Voyager Therapeutics
                  Compugen
                  XTL Biopharmaceuticals Ltd. Sponsored ADR
                  Oramed Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis